Amgen Researchers Crack Weight-Loss Hormone Paradox

Amgen Inc. researchers have made a significant discovery in obesity drug development. They've found a clue to explain why blocking a hormone can help people lose weight, despite activating the same hormone also working.

The team is testing an obesity therapy that mimics the GLP-1 hormone, while blocking another gut hormone called GIP. This approach is being compared to Eli Lilly & Co.'s blockbuster Zepbound, which activates both hormones.

The findings of this research could have significant implications for the development of weight-loss drugs and may provide a clue to one of the more puzzling questions in obesity treatment.